BridgeBio Pharma, Inc.
BBIO
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 cliniā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$47.27
Price+3.62%
$1.65
1Y
Price
Market Cap
$8.976b
Mid
Price/Earnings 3y Avg5y Avg
-16.6x
Premium
Premium
Dividends
Ex-Dividend: -0.00%
Yield$0.00
Dividend0.00%
Forward Dividend Growth 3y CAGR5y CAGR
0.0%
Premium
Premium
Payout Payout 3yPayout 5y
0.0%
Premium
Premium
Yield
BenchmarkDividends
No items found.
Financials Overview
Key metrics over the past few years-8096.8%
EBITDA Margin-3388.2%
Net Profit Margin-
Free Cash Flow MarginRevenue
$221.902m
+2255.4%
1y CAGR+726.3%
3y CAGR+731.0%
5y CAGREarnings
-$535.762m
+29.4%
1y CAGR+7.3%
3y CAGR-2.5%
5y CAGREPS
-$2.85
+33.4%
1y CAGR+13.3%
3y CAGR+8.0%
5y CAGRBook Value
-$1.468b
$919.338m
Assets$2.377b
Liabilities$1.731b
DebtDebt to Assets
188.2%
-4x
Debt to EBITDAFree Cash Flow
-$529.634m
+7.0%
1y CAGR+1.6%
3y CAGR-7.3%
5y CAGRFinancial Reports
Earnings and other important metricsNo items found.
Press Releases
Statements and updates from the company